Nestlé says its nutrition therapy biz could be worth $10B; Sanders campaign rejects Shkreli donation;

@FierceBiotech: FierceBiotech Radio on Lilly's latest pipeline peril, Mylan's M&A broken record, and German Merck's big rebrand. More | Follow @FierceBiotech

@JohnCFierce: Zafgen hammered (again) as FDA clamps partial hold on PhIII obesity drug. Report | Follow @JohnCFierce

@DamianFierce: Lost in all this is that "Theranos" would have been a great name for a black metal band. | Follow @DamianFierce

> Nestlé believes its nascent nutritional therapy business, meant to bridge the gap between food and pharma, can eventually grow into a $10 billion enterprise. News

> Hong Kong's Hutchison China MediTech is plotting a $100 million IPO to advance its pipeline of immuno-oncology therapies. More

> Martin Shkreli, the controversial CEO of Turing Pharmaceuticals, made a $2,700 donation to Sen. Bernie Sanders' presidential effort, a gift the campaign said it will donate to charity. Story

Medical Device News

@FierceMedDev: Check out this year's Fierce 15: The new strategic med tech mania sets the stage for 2015's Fierce 15. Feature | Follow @FierceMedDev

@VarunSaxena2: #TCT15: Startup's minimally invasive mitral valve repair tech shows promise in feasibility study. Article | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: 23andMe adds chapter to comeback story with $115M in funding. Report | Follow @EmilyWFierce

> Theranos dials down lab testing amid FDA pushback. Story

> WSJ: Former Theranos employees reveal problems with proprietary testing device. More

Pharma News

@FiercePharma: India pharma sees trouble for its industry in newly negotiated TPP. More | Follow @FiercePharma

@EricPFierce: Pests, lack of data integrity thwart another Indian API maker, this time Unimark Remedies. News | Follow @EricPFierce

@CarlyHFierce: After FDA snub, AZ diabetes combo faces potential years-long delay. Article | Follow @CarlyHFierce

> U.K. cost watchdog gives thumbs-up to Bristol-Myers' hep C drug. Story

> FDA's review of BI's Pradaxa was 'lax' and 'permissive,' watchdog claims. Article

Suggested Articles

The analysis found Nexvax2 was no better than placebo at protecting patients from gluten, prompting the Arch-backed biotech to stop the study.

Johns Hopkins scientists found that misfolded alpha-synuclein protein can travel from the gut and drive Parkinson's disease.

The financing sets Sanifit up to take its lead drug through phase 3 while exploring its potential in other progressive vascular calcification disorders.